In the bioscience sector, the focus is majorly on Haleon with several news entities reporting GSK and Pfizer selling stakes in the company. GSK is offloading their entire Haleon stake, with some accounts revealing a sale of 4.2% stake and around $1.24 billion from the latest sale. Similarly, Pfizer is reducing its stake in the company from 32% to 24% in a sale amounting to approximately $2.6 billion. Medicinal and healthcare product giant, Haleon has shown strong Financial Year (FY) results and is implementing a share buyback scheme, leading to a 5% rise in shares. Moreover, reports on their FY23 earnings demonstrated a miss in the EPS, although investor demand remains high. Haleon also announced a major offering, whereas Russell Investments Group increased their stock position in Haleon. The company plans to sell the ChapStick brand to Suave for $430 million. Interestingly, Morgan Stanley is adjusting its focus on Haleon's Q1 growth forecast despite signs of temporary pressure in Q1 earnings.
Haleon Stocks News Analytics from Thu, 13 Jul 2023 07:00:00 GMT to Thu, 16 May 2024 16:47:25 GMT - Rating 4 - Innovation 2 - Information 5 - Rumor 1
